Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing SINGAPORE , Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home. The program combines the Camtech Health HPV (human papillomavirus) test for self-collection with the BD Onclarity™ HPV Assay, which is a clinically validated test that can simultaneously detect 14 high-risk HPV strains (or "genotypes").

BD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

FRANKLIN LAKES, N.J. , Feb. 15, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: Citi's 2024 Unplugged Medtech and Life Sciences Access Day February 29, 2024 8:00 am Eastern Time Barclays 26th Annual Global Healthcare Conference March 13, 2024 9:30 am Eastern Time The live webcasts of BD's presentations can be accessed from the BD investor relations website, investors.bd.com.

BD to Present at Investor Healthcare Conferences

West Pharmaceutical Services

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?

BDX or WST: Which Is the Better Value Stock Right Now?

FRANKLIN LAKES, N.J. , Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.

BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease

BD's (BDX) slew of product launches raises optimism about the stock.

Three Reasons to Retain BD (BDX) Stock in Your Portfolio

Becton, Dickinson and Company (BDX) Q1 2024 Earnings Call Transcript

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.

BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Becton Dickinson (BDX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Becton Dickinson (BDX) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.98 per share a year ago.

Becton Dickinson (BDX) Q1 Earnings Surpass Estimates

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson beat first-quarter profit estimates and raised its full-year earnings forecast on Thursday as it benefits from strong demand for its surgical equipment.

Becton Dickinson lifts 2024 profit forecast on surgical devices strength

Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q1 revenue of $4.7 billion increased 2.6% as reported, 1.6% currency-neutral and 2.4% organic Q1 GAAP and adjusted diluted EPS from continuing operations of $0.96 and $2.68, respectively Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance FRANKLIN LAKES, N.J. , Feb. 1, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2024, which ended December 31, 2023.

BD Reports First Quarter Fiscal 2024 Financial Results

BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.

BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test

AI-Based Algorithm Aims to Enable Cytotechnologists and Pathologists to Efficiently Identify Evidence of Cervical Cancer and Precancerous Lesions FRANKLIN LAKES, N.J. and OREM, Utah , Jan. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, today announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging.

BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Becton Dickinson (BDX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

BD (BDX) Collaborates With Hamilton to Benefit Researchers

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline

Collaboration with Kenya Ministry of Health National Cancer Institute Aims to Expand Access to Diagnostics, Reduce Cervical Cancer Rates NAIROBI, Kenya , Jan. 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to advance access to critical cancer diagnostics for women in Kenya. Through this program, BD continues to drive its commitment toward progress of advancing health equity to underserved communities around the world.

BD Helps Advance Health Equity for Women in Kenya through Critical Cancer Screening

Companies to automate a critical step of high-throughput single-cell multiomics experiments FRANKLIN LAKES, N.J. , Jan. 23, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics

Becton, Dickinson and Company has underperformed the market and healthcare sector in recent years. The company's balance sheet has improved significantly which I believe will allow for increased returns of capital to shareholders going forward. BDX's recent guidance for FY 2024 has lowered earnings expectations, but the company has a history of beating consensus estimates.

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

In an interview with CNBC's Jim Cramer, Becton Dickinson CEO Tom Polen described how the medical device manufacturer's new technology can save hospitals money.

Becton Dickinson CEO describes how new technology helps hospitals fight inflated operating costs

Survey Conducted in the US, UK and Sweden Exposes Lack of Education on Options and Unclear Guidance on HPV Testing FRANKLIN LAKES, N.J. , Jan. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a Harris Poll survey of women in the U.S., U.K. and Sweden, which shines a spotlight on the differences in access to cervical cancer screening and prevention.

New Survey by The Harris Poll Highlights Gaps in Cervical Cancer Screening Access

FRANKLIN LAKES, N.J. , Jan. 5, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2024, at 1:00 p.m.

BD Announces Webcast of Annual Meeting of Shareholders

FRANKLIN LAKES, N.J., Jan. 4, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its first quarter of fiscal year 2024 on Thursday, February 1, 2024.

News for Becton, Dickinson and Co. Stock (BDX)